Salarius Pharmaceuticals Inc. [NASDAQ: SLRX] price surged by 10.36 percent to reach at $0.2. The company report on February 24, 2021 that Salarius Pharmaceuticals Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas.
Relapsed and refractory Ewing sarcoma patients to receive seclidemstat in combination with chemotherapy agents as second- and third-line therapy; Protocol amendment expands and improves access to addressable patient population.
Ewing-related sarcoma patients to receive single-agent therapy supported by preliminary signs of drug activity indicating an increase in patients time to progression.
A sum of 16517460 shares traded at recent session while its average daily volume was at 2.54M shares. Salarius Pharmaceuticals Inc. shares reached a high of $2.70 and dropped to a low of $2.07 until finishing in the latest session at $2.13.
Guru’s Opinion on Salarius Pharmaceuticals Inc. [SLRX]:
Ladenburg Thalmann have made an estimate for Salarius Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 27, 2020.
The Average True Range (ATR) for Salarius Pharmaceuticals Inc. is set at 0.37, with the Price to Sales ratio for SLRX stock in the period of the last 12 months amounting to 10.30. The Price to Book ratio for the last quarter was 1.85, with the Price to Cash per share for the same quarter was set at 0.41.
SLRX Stock Performance Analysis:
Salarius Pharmaceuticals Inc. [SLRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -21.11. With this latest performance, SLRX shares gained by 65.12% in over the last four-week period, additionally plugging by 126.33% over the last 6 months – not to mention a rise of 158.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLRX stock in for the last two-week period is set at 55.30, with the RSI for the last a single of trading hit 50.97, and the three-weeks RSI is set at 57.50 for Salarius Pharmaceuticals Inc. [SLRX]. The present Moving Average for the last 50 days of trading for this stock 1.41, while it was recorded at 2.19 for the last single week of trading, and 1.13 for the last 200 days.
Insight into Salarius Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Salarius Pharmaceuticals Inc. [SLRX] shares currently have an operating margin of -238.53. Salarius Pharmaceuticals Inc.’s Net Margin is presently recorded at -200.23.
Return on Total Capital for SLRX is now -81.17, given the latest momentum, and Return on Invested Capital for the company is -69.86. Return on Equity for this stock declined to -69.86, with Return on Assets sitting at -57.14. When it comes to the capital structure of this company, Salarius Pharmaceuticals Inc. [SLRX] has a Total Debt to Total Equity ratio set at 4.75. Additionally, SLRX Total Debt to Total Capital is recorded at 4.53, with Total Debt to Total Assets ending up at 3.62.
Reflecting on the efficiency of the workforce at the company, Salarius Pharmaceuticals Inc. [SLRX] managed to generate an average of -$867,262 per employee. Receivables Turnover for the company is 697.26 with a Total Asset Turnover recorded at a value of 0.29.Salarius Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 5.70.
SLRX Stock EPS
With the latest financial reports released by the company, Salarius Pharmaceuticals Inc. posted -12.5/share EPS, while the average EPS was predicted by analysts to be reported at -11.25/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SLRX.
Salarius Pharmaceuticals Inc. [SLRX] Insider Position Details
There are presently around $9 million, or 13.10% of SLRX stock, in the hands of institutional investors. The top three institutional holders of SLRX stocks are: SIO CAPITAL MANAGEMENT, LLC with ownership of 1,657,242, which is approximately New of the company’s market cap and around 0.50% of the total institutional ownership; AIGH CAPITAL MANAGEMENT LLC, holding 1,505,985 shares of the stock with an approximate value of $3.21 million in SLRX stocks shares; and WORTH VENTURE PARTNERS, LLC, currently with $0.77 million in SLRX stock with ownership of nearly 39.616% of the company’s market capitalization.
Positions in Salarius Pharmaceuticals Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 13 institutional holders increased their position in Salarius Pharmaceuticals Inc. [NASDAQ:SLRX] by around 3,585,728 shares. Additionally, 4 investors decreased positions by around 69,929 shares, while 9 investors held positions by with 607,539 shares. The mentioned changes placed institutional holdings at 4,263,196 shares, according to the latest SEC report filing. SLRX stock had 8 new institutional investments in for a total of 3,324,123 shares, while 1 institutional investors sold positions of 11,621 shares during the same period.